Next Article in Journal
Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
Previous Article in Journal
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics
Article

Therapeutic Efficacy of Anti-Bestrophin Antibodies against Experimental Filariasis: Immunological, Immune-Informatics and Immune Simulation Investigations

1
Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol 713340, West Bengal, India
2
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Universités, Université de Paris, F-75006 Paris, France
3
Indian Institute of Technology Palakkad, Palakkad 678623, Kerala, India
*
Authors to whom correspondence should be addressed.
Academic Editor: Angray S. Kang
Antibodies 2021, 10(2), 14; https://doi.org/10.3390/antib10020014
Received: 31 December 2020 / Revised: 13 April 2021 / Accepted: 14 April 2021 / Published: 17 April 2021
Lymphatic filariasis (LF) is a debilitating parasitic disease caused by filarial parasites and it is prevalent across the underprivileged population throughout the globe. The inadequate efficacy of the existing treatment options has provoked the conception of alternative strategies, among which immunotherapy is steadily emerging as a promising option. Herein, we demonstrate the efficacy of an antibody-based immunotherapeutic approach in an experimental model of filariasis, i.e., Wistar rat infected with Setaria cervi (a model filarial parasite). The polyclonal antibodies were raised against filarial surface antigen bestrophin protein (FSAg) in mice using the purified Wuchereria bancrofti FSAg. The adoptive transfer of anti-FSAg antibody-containing serum resulted in the significant reduction of parasite burden in filaria-infected rats. Intriguingly, anti-FSAg sera-treated animals also displayed a reduction in the level of proinflammatory cytokines as compared to the infected but untreated group. Furthermore, our in silico immunoinformatics data revealed eight B-cell epitopes and several T-cell epitopes in FSAg and these epitopes were linked to form a refined antigen in silico. The immune simulation suggested IgM and IgG1 as the predominant immunoglobulins induced in response to FSAg. Taken together, our experimental and simulation data collectively indicated a therapeutic potential of anti-FSAg sera against LF. View Full-Text
Keywords: lymphatic filariasis; filarial parasites; bestrophin; anti-FSAg antibody; antibody therapy; in silico analyses lymphatic filariasis; filarial parasites; bestrophin; anti-FSAg antibody; antibody therapy; in silico analyses
Show Figures

Graphical abstract

MDPI and ACS Style

Das, N.C.; Ray, A.S.; Bayry, J.; Mukherjeee, S. Therapeutic Efficacy of Anti-Bestrophin Antibodies against Experimental Filariasis: Immunological, Immune-Informatics and Immune Simulation Investigations. Antibodies 2021, 10, 14. https://doi.org/10.3390/antib10020014

AMA Style

Das NC, Ray AS, Bayry J, Mukherjeee S. Therapeutic Efficacy of Anti-Bestrophin Antibodies against Experimental Filariasis: Immunological, Immune-Informatics and Immune Simulation Investigations. Antibodies. 2021; 10(2):14. https://doi.org/10.3390/antib10020014

Chicago/Turabian Style

Das, Nabarun C., Anindya S. Ray, Jagadeesh Bayry, and Suprabhat Mukherjeee. 2021. "Therapeutic Efficacy of Anti-Bestrophin Antibodies against Experimental Filariasis: Immunological, Immune-Informatics and Immune Simulation Investigations" Antibodies 10, no. 2: 14. https://doi.org/10.3390/antib10020014

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop